DMXAA was originally created as a vasculature disruption agent but was incidentally discovered to directly bind to and activate STING in mouse model studies.59 Subsequent studies have shown that DMXAA has a high affinity for murine STING but not for human STING,59 which accounts for the mostly negative results from treating cancer patients with DMXAA (Table 1). The gene discussed is STING1; the disease is cancer.